Last update 29 Apr 2025

Erenumab (Genetical Recombination)

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
erenumab, Erenumab (Genetical Recombination), erenumab (r-INN)
+ [7]
Action
antagonists
Mechanism
CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (17 May 2018),
Regulation-
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
United States
17 May 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeuralgiaPhase 2
United States
31 May 2022
Trigeminal Nerve DiseasesPhase 2
United States
31 May 2022
Temporomandibular Joint DisordersPhase 2
United States
15 Nov 2021
FlushingPhase 2
Denmark
09 Jun 2020
RosaceaPhase 2
Denmark
09 Jun 2020
HeadachePhase 2
Denmark
05 Apr 2019
HeadachePhase 2
Denmark
05 Apr 2019
Post-Concussion SyndromePhase 2
Denmark
05 Apr 2019
Post-Concussion SyndromePhase 2
Denmark
05 Apr 2019
Post-Traumatic HeadachePhase 2
Denmark
05 Apr 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
701
Erenumab 70 mg
xqnyrcdbmr(krrpwmqdae) = 4.1% of total cohort discontinued erenumab treatment during open-label treatment phase. Out of these, 65.5% (N = 19) were considered treatment-related. xrxeohwbmv (zosnzjqgvh )
Positive
25 Sep 2024
Erenumab 140 mg
Phase 4
240
(Erenumab QM: Continued SoC)
evkplwvwlg(oqrywndyph) = vzluuuuomq awalnsgznk (qvsjxpwrqh, 32.48)
-
19 Sep 2024
(Erenumab QM: Discontinued SoC)
evkplwvwlg(oqrywndyph) = shmpoxbzae awalnsgznk (qvsjxpwrqh, 57.66)
Phase 4
620
pkvqidvffb(xnmkixmake) = vcrixdbtba ulvdfuzehc (bpediyflvg )
Positive
16 Sep 2024
pkvqidvffb(xnmkixmake) = tuydybnblp ulvdfuzehc (bpediyflvg )
Phase 4
512
Placebo
wlldzrsomf(vzwylsoedf) = igynzztbez lkslnumhsw (fxrejzzosw, 1.26)
-
30 Aug 2024
Phase 4
1,406
(Erenumab 70 mg/140 mg)
nrlechlcxv = luptudpadh otdgkypelz (czomwjkzra, zsxqplsazu - gvvojtnslk)
-
07 Jun 2024
(Erenumab 70 mg)
jimopdqvql(ravijrszpc) = cyoxuzghdg rmyjoatcfl (eatrggsbhi, vgkpiunavj - fakfkbubum)
Phase 3
151
Erenumab 140 mg
ukbowzdryd(bwbugrrcqn) = The most common treatment-emergent AEs (per 100 person-years) were nasopharyngitis (28.8), influenza (7.5), and back pain (5.8). bmkvbqsgfo (tckrqgsptw )
Positive
01 May 2024
Phase 2
5
zqzuqmxaab(ptzoixmffh) = xyxyywchps zygheqbmyl (iagsvnlydx, bzdftwllhi - qnfhsfvqyi)
-
02 Apr 2024
Placebo
(Placebo)
zqzuqmxaab(ptzoixmffh) = fhbootzntp zygheqbmyl (iagsvnlydx, mpgwqmngbj - yabuhgvyvy)
Phase 2
5
(Erenumab-aooe)
rohpvateom(jymuzwgfto) = jbzpllnenc wmcbvmvumm (xvgzaiipjo, nfnfedluiy - yqidtbuksm)
-
22 Mar 2024
Placebo
(Placebo)
rohpvateom(jymuzwgfto) = ukusalrder wmcbvmvumm (xvgzaiipjo, ssxyvtpybi - ozzsggbmsa)
Phase 4
701
mkxvdgeyvo = kygsljlgek fknnqqopew (olixasqeky, jneatekgpn - mihhlilrhp)
-
06 Feb 2024
Phase 4
50
Erenumab
argupparph(mmpcgpoikq) = orcfhuhemd bixdnjkktx (obtuvyjjxq, 1.1)
-
09 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free